Axsome Therapeutics (AXSM) Operating Margin: 2022-2025
Historic Operating Margin for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to -26.97%.
- Axsome Therapeutics' Operating Margin rose 3281.00% to -26.97% in Q3 2025 from the same period last year, while for Sep 2025 it was -37.85%, marking a year-over-year increase of 5263.00%. This contributed to the annual value of -72.74% for FY2024, which is 1293.00% up from last year.
- Latest data reveals that Axsome Therapeutics reported Operating Margin of -26.97% as of Q3 2025, which was down 10.20% from -24.47% recorded in Q2 2025.
- Axsome Therapeutics' Operating Margin's 5-year high stood at -6.74% during Q1 2023, with a 5-year trough of -251.76% in Q3 2022.
- Moreover, its 3-year median value for Operating Margin was -61.14% (2024), whereas its average is -71.77%.
- Per our database at Business Quant, Axsome Therapeutics' Operating Margin skyrocketed by 14,428bps in 2023 and then plummeted by 8,296bps in 2024.
- Over the past 4 years, Axsome Therapeutics' Operating Margin (Quarterly) stood at -245.86% in 2022, then spiked by 10,847bps to -137.39% in 2023, then spiked by 7,625bps to -61.14% in 2024, then surged by 3,281bps to -26.97% in 2025.
- Its Operating Margin was -26.97% in Q3 2025, compared to -24.47% in Q2 2025 and -46.91% in Q1 2025.